Who are Active bupropion + counseling's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/active-bupropion-counseling.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Active bupropion + counseling — Competitive Intelligence Brief

Active bupropion + counseling (Active bupropion + counseling) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidepressant (dopamine-norepinephrine reuptake inhibitor). Area: Psychiatry / Addiction Medicine.

marketed Antidepressant (dopamine-norepinephrine reuptake inhibitor) Dopamine transporter (DAT), Norepinephrine transporter (NET) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Active bupropion + counseling (Active bupropion + counseling) — University of Wisconsin, Madison. Bupropion inhibits the reuptake of dopamine and norepinephrine in the central nervous system, increasing their availability to enhance mood and motivation, while counseling provides behavioral support for smoking cessation or other psychiatric conditions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active bupropion + counseling TARGET	Active bupropion + counseling	University of Wisconsin, Madison	marketed	Antidepressant (dopamine-norepinephrine reuptake inhibitor)	Dopamine transporter (DAT), Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidepressant (dopamine-norepinephrine reuptake inhibitor) class)

University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Active bupropion + counseling — Competitive Intelligence Brief. https://druglandscape.com/ci/active-bupropion-counseling. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab